Cantor Fitzgerald set a $23.00 price objective on Mesoblast (NASDAQ:MESO) in a research note issued to investors on Tuesday, TipRanks reports. The firm currently has a buy rating on the stock.

A number of other research analysts have also issued reports on MESO. Chardan Capital set a $6.00 target price on shares of Mesoblast and gave the company a hold rating in a research note on Friday, August 30th. HC Wainwright set a $7.00 target price on shares of Mesoblast and gave the company a buy rating in a research note on Friday, August 30th. Oppenheimer set a $10.00 target price on shares of Mesoblast and gave the company a buy rating in a research note on Tuesday. Maxim Group reiterated a buy rating and issued a $16.00 target price on shares of Mesoblast in a research note on Wednesday, June 12th. Finally, ValuEngine raised shares of Mesoblast from a hold rating to a buy rating in a report on Tuesday. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Mesoblast currently has a consensus rating of Buy and an average price target of $11.25.

NASDAQ:MESO traded up $0.58 during midday trading on Tuesday, reaching $7.33. The stock had a trading volume of 608 shares, compared to its average volume of 43,361. Mesoblast has a 1-year low of $3.35 and a 1-year high of $8.78. The firm’s fifty day simple moving average is $5.06 and its 200-day simple moving average is $5.09. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.41 and a quick ratio of 1.92. The stock has a market capitalization of $572.56 million, a P/E ratio of -7.89 and a beta of 1.77.

Mesoblast (NASDAQ:MESO) last posted its earnings results on Thursday, August 29th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. Mesoblast had a negative net margin of 536.97% and a negative return on equity of 17.66%. The business had revenue of $1.97 million for the quarter, compared to analyst estimates of $1.31 million. On average, equities research analysts anticipate that Mesoblast will post -0.86 earnings per share for the current fiscal year.

An institutional investor recently raised its position in Mesoblast stock. Morgan Stanley raised its stake in Mesoblast limited (NASDAQ:MESO) by 284.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 147,702 shares of the company’s stock after purchasing an additional 109,295 shares during the period. Morgan Stanley owned approximately 0.16% of Mesoblast worth $784,000 as of its most recent SEC filing. 2.76% of the stock is currently owned by hedge funds and other institutional investors.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Recommended Story: The primary rules of Elliott Wave theory

Analyst Recommendations for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.